WO2000053148A3 - Procedes et compositions pour le traitement de la dyserection - Google Patents

Procedes et compositions pour le traitement de la dyserection Download PDF

Info

Publication number
WO2000053148A3
WO2000053148A3 PCT/US2000/005711 US0005711W WO0053148A3 WO 2000053148 A3 WO2000053148 A3 WO 2000053148A3 US 0005711 W US0005711 W US 0005711W WO 0053148 A3 WO0053148 A3 WO 0053148A3
Authority
WO
WIPO (PCT)
Prior art keywords
erectile dysfunction
methods
present
compositions
treating erectile
Prior art date
Application number
PCT/US2000/005711
Other languages
English (en)
Other versions
WO2000053148A2 (fr
Inventor
Elizabeth Stoner
Original Assignee
Merck & Co Inc
Waldstreicher Joanne
Elizabeth Stoner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Waldstreicher Joanne, Elizabeth Stoner filed Critical Merck & Co Inc
Priority to CA002362918A priority Critical patent/CA2362918A1/fr
Priority to EP00916081A priority patent/EP1161255A4/fr
Priority to AU37244/00A priority patent/AU3724400A/en
Publication of WO2000053148A2 publication Critical patent/WO2000053148A2/fr
Publication of WO2000053148A3 publication Critical patent/WO2000053148A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur un procédé de traitement de la dysérection affectant l'homme ou la femme. Ce procédé consiste à administrer une quantité thérapeutiquement efficace d'un agoniste du récepteur de la mélanocortine en combinaison avec une quantité thérapeutiquement efficace d'un inhibiteur de phosphodiestérase spécifique de GMP cyclique ou d'un antagoniste du récepteur alpha adrénergique. Cette invention porte également sur les compositions pharmaceutiques utiles dans les procédés de l'invention, ainsi que sur un procédé de fabrication d'un médicament utile pour traiter la dysérection.
PCT/US2000/005711 1999-03-08 2000-03-03 Procedes et compositions pour le traitement de la dyserection WO2000053148A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002362918A CA2362918A1 (fr) 1999-03-08 2000-03-03 Procedes et compositions pour le traitement de la dyserection
EP00916081A EP1161255A4 (fr) 1999-03-08 2000-03-03 Procedes et compositions pour le traitement de la dyserection
AU37244/00A AU3724400A (en) 1999-03-08 2000-03-03 Methods and compositions for treating erectile dysfunction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12324499P 1999-03-08 1999-03-08
US60/123,244 1999-03-08

Publications (2)

Publication Number Publication Date
WO2000053148A2 WO2000053148A2 (fr) 2000-09-14
WO2000053148A3 true WO2000053148A3 (fr) 2000-12-14

Family

ID=22407530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005711 WO2000053148A2 (fr) 1999-03-08 2000-03-03 Procedes et compositions pour le traitement de la dyserection

Country Status (4)

Country Link
EP (1) EP1161255A4 (fr)
AU (1) AU3724400A (fr)
CA (1) CA2362918A1 (fr)
WO (1) WO2000053148A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
NO20002097L (no) * 1999-04-30 2001-10-26 Lilly Icos Llc Fremstillingsgjenstander
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7182958B1 (en) 1999-08-03 2007-02-27 Lilly Icos Llc. β-carboline pharmaceutical compositions
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
JP4336196B2 (ja) * 2001-07-18 2009-09-30 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作動薬としての架橋ピペリジン誘導体
BR0305628A (pt) 2002-07-09 2004-09-08 Palatin Technologies Inc Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028902A1 (fr) * 1993-06-09 1994-12-22 Pfizer Limited Pyrazolopyrimidinones utilisees pour traiter l'impuissance
WO1996016657A1 (fr) * 1994-11-26 1996-06-06 Pfizer Limited Composes heterocycliques bicycliques destines au traitement de l'impuissance
US5567706A (en) * 1993-02-10 1996-10-22 Gavras; Haralambos Method for treating impotence
US5576290A (en) * 1993-04-05 1996-11-19 Competitive Technologies, Inc. Compositions and methods for the diagnosis and treatment of psychogenic erectile dysfunction
WO1997003675A1 (fr) * 1995-07-14 1997-02-06 Icos Corporation Utilisation d'inhibiteurs de phosphodiesterase specifique de gmpc dans le traitement de l'impuissance
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
WO1999030697A2 (fr) * 1997-12-16 1999-06-24 Pfizer Products Inc. Composition efficace pour le traitement de l'impuissance
WO1999030718A2 (fr) * 1997-12-18 1999-06-24 Nathan Earl Scott COMBINAISON DE PROSTAGLANDINES E2/F2α, DESTINEE AU TRAITEMENT DE L'IMPUISSANCE ET A L'ACCROISSEMENT DE L'EXCITATION SEXUELLE
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5962528A (en) * 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
WO1999059584A1 (fr) * 1998-05-20 1999-11-25 Schering Corporation Combinaison de phentolamine et d'inhibiteurs de la phosphodiesterase gmp cyclique utilises dans le traitement des dysfonctions sexuelles
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
EP0960621A2 (fr) * 1998-05-15 1999-12-01 Pfizer Inc. Compositions pharmaceutiques comprenant du sildenafil
WO1999060985A2 (fr) * 1998-05-26 1999-12-02 Saint Louis University Composes, compositions et methodes de traitement de la dyserection
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
WO1999066933A1 (fr) * 1998-06-25 1999-12-29 New Millennium Pharmaceutical Research, Inc. Traitement de la dyserection par administration de sildenafil par voie nasale
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962528A (en) * 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
US5567706A (en) * 1993-02-10 1996-10-22 Gavras; Haralambos Method for treating impotence
US5576290A (en) * 1993-04-05 1996-11-19 Competitive Technologies, Inc. Compositions and methods for the diagnosis and treatment of psychogenic erectile dysfunction
US6051555A (en) * 1993-04-05 2000-04-18 Hadley; Mac E. Stimulating sexual response in females
WO1994028902A1 (fr) * 1993-06-09 1994-12-22 Pfizer Limited Pyrazolopyrimidinones utilisees pour traiter l'impuissance
WO1996016657A1 (fr) * 1994-11-26 1996-06-06 Pfizer Limited Composes heterocycliques bicycliques destines au traitement de l'impuissance
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
WO1997003675A1 (fr) * 1995-07-14 1997-02-06 Icos Corporation Utilisation d'inhibiteurs de phosphodiesterase specifique de gmpc dans le traitement de l'impuissance
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO1999030697A2 (fr) * 1997-12-16 1999-06-24 Pfizer Products Inc. Composition efficace pour le traitement de l'impuissance
WO1999030718A2 (fr) * 1997-12-18 1999-06-24 Nathan Earl Scott COMBINAISON DE PROSTAGLANDINES E2/F2α, DESTINEE AU TRAITEMENT DE L'IMPUISSANCE ET A L'ACCROISSEMENT DE L'EXCITATION SEXUELLE
EP0960621A2 (fr) * 1998-05-15 1999-12-01 Pfizer Inc. Compositions pharmaceutiques comprenant du sildenafil
WO1999059584A1 (fr) * 1998-05-20 1999-11-25 Schering Corporation Combinaison de phentolamine et d'inhibiteurs de la phosphodiesterase gmp cyclique utilises dans le traitement des dysfonctions sexuelles
WO1999060985A2 (fr) * 1998-05-26 1999-12-02 Saint Louis University Composes, compositions et methodes de traitement de la dyserection
WO1999066933A1 (fr) * 1998-06-25 1999-12-29 New Millennium Pharmaceutical Research, Inc. Traitement de la dyserection par administration de sildenafil par voie nasale
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1161255A4 *

Also Published As

Publication number Publication date
EP1161255A2 (fr) 2001-12-12
EP1161255A4 (fr) 2002-07-17
AU3724400A (en) 2000-09-28
WO2000053148A2 (fr) 2000-09-14
CA2362918A1 (fr) 2000-09-14

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2005107726A3 (fr) Procede pour le traitement de mal de dos
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
DE60038290D1 (de) Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
EP1426375A3 (fr) Dérivés analgétiques de spiroindole
WO2004005324A3 (fr) Composition peptidique pour le traitement de la dysfonction sexuelle
EP1149579A3 (fr) Utilisation d'un agoniste/antagoniste estrogenique pour traiter le dysfonctionnement sexuel chez la femme
AU2003296993A8 (en) Cyclopropyl compounds as ccr5 antagonists
WO2002099388A3 (fr) Benzodiazepines antagonistes de bradykinine
WO2006049933A3 (fr) Compositions et procedes de traitement de l'obesite et du dysfonctionnement sexuel
WO2002060392A3 (fr) Utilisation d'antagonistes du recepteur gal3 dans le traitement de la depression et/ou de l'anxiete et composes utiles dans de telles methodes
AU5895496A (en) Phenyldihydrobenzofurans
WO2002070524A3 (fr) N-but-3-enyl norbuprenorphine et utilisations
WO2006047392A3 (fr) Synergie entre nicotine et opioides a des fins d'analgesie
WO2000053148A3 (fr) Procedes et compositions pour le traitement de la dyserection
WO2001001972A3 (fr) ANTAGONISTES SELECTIFS DU RECEPTEUR iGluR5 UTILISES DANS LE TRAITEMENT DE LA MIGRAINE
EP1415652A3 (fr) Composition comprenant des inhibiteurs de la phosphodiesterase pour traiter les disfonctionnements sexuels
BG105664A (en) Use of apomophines for the treatment of organic erectile dysfunction in males
CY2462B1 (en) Cyclohexyl dihydrobenzofuranes.
EP1064966A3 (fr) Combinaisons d'agonistes de recepteurs de 5HT 1, de cafeine et d'inhibiteurs de cyclooxygenase-2 pour le traitement de la migraine
WO2001045715A3 (fr) Formulations d'agonistes d'adenosine a1
HUP0402358A2 (hu) Szelektív dopamin D4 receptor agonisták alkalmazása szexuális diszfunkciók kezelésére alkalmas gyógyszerkészítmény előállítására
EP0799618A3 (fr) Utilisation d'antagonistes de l'adrénorécepteur alpha 1 dans la fabrication d'unmédicament pur la prévention et au traitment du cancer
WO1999065475A3 (fr) Combinaison de phentolamine et apomorphine pour le traitement concernant les fonctions et les dysfonctionnements sexuels

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 37244/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2362918

Country of ref document: CA

Ref document number: 2362918

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000916081

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 603637

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000916081

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000916081

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)